Table 1

Study overview

Author,
reference number
Patients
(primary tumours)
Chemotherapeutic agents, duration, temperature
Refaely et al18n=15 (thymoma/TC)Cisplatin (100 mg/m2 BSA); 60 min; 42°C
de Bree et al5n=3 (thymoma/TC) n=11 (MPM)Cisplatin (80 mg/m2 BSA)+doxorubicin (15–30 mg/m2 BSA); 90 min; 40°C–41°C
Richards et al6n=44 (MPM)Cisplatin (low-dose: 50–150 mg/m2 BSA; high-dose: 175–250 mg/m2 BSA); 60 min; 42°C
Zellos et al11n=29 (MPM)Cisplatin (75–200 mg/m2 BSA); 60 min; 42°C
Tillemann et al12n=92 (MPM)Cisplatin (225 mg/m2 BSA); 60 min; 42°C
Ried et al2n=8 (MPM) n=8 (thymoma/TC)Cisplatin (100–150 mg/m2 BSA); 60 min; 42°C
Sugarbaker et al1n=72 (MPM)Cisplatin (175–225 mg/m2 BSA); 60 min; 42°C
Yellin et al26n=35 (thymoma/TC)Cisplatin (100 mg/m2 BSA)+doxorubicin (50–60 mg), 60 min; 43°C
Yu et al19n=4 (thymoma/TC)Cisplatin (100 mg/m2 BSA); 120 min; 41°C–43°C
Migliore et al4n=6 (MPM) n=2 (lung cancer)Cisplatin (120 mg/m2 BSA); 60 min; 42.5°C
Ishibashi et al27n=14 (MPM)Cisplatin (80 mg/m2 BSA); 60 min; 42°C
Ambrogi et al20n=13 (thymoma/TC)Cisplatin (80 mg/m2 BSA)+doxorubicin (25 mg/m2 BSA); 60 min; 42.5°C
Bertoglio et al30n=26 (MPM)Cisplatin (80 mg/m2 BSA)+doxorubicin (25 mg/m2 BSA); 60 min; 42.5°C
Maury et al25n=19 (thymoma/TC)Cisplatin (50 mg/m2 BSA)+mitomycin (25 mg/m2 BSA); 90 min; 42°C
Ambrogi et al8n=49 (MPM)Cisplatin (80 mg/m2 BSA)+epirubicin (25 mg/m2 BSA); 60 min; 42.5°C
Burt et al7n=104 (MPM)Cisplatin (175–225 mg/m2 BSA)+gemcitabine (100–1200 mg/m2 BSA); 60 min; 40°C–42°C
Markowiak et al3n=29 (thymoma/TC)Cisplatin (100–175 mg/m2 BSA)+doxorubicin (0–65 mg); 60 min; 42°C
  • BSA, body surface area; MPM, malignant pleural mesothelioma; TC, thymic carcinoma.